- Participants debated whether long-acting subdermal drug-delivery implants could mitigate the fentanyl crisis by providing tightly controlled, auto-tapering dosing for either addiction recovery or chronic-pain management, citing the FDA-approved six-month buprenorphine Probuphine® implant (four 26 mm × 2.5 mm ethylene-vinyl-acetate rods) as a working precedent.  
- The discussion highlighted fentanyl’s unique danger: microgram potency makes it cheap to smuggle and easy to adulterate other drugs (e.g., LSD), driving overdose spikes—especially in San Francisco—while free fentanyl test strips already exist but are unevenly available.  
- A complementary proposal called for open-source, pocket-sized chemical analyzers—Raman spectroscopy, X-ray fluorescence, or miniature mass-spec—to give individuals on-the-spot detection of fentanyl and other contaminants beyond what test strips cover.  
- One participant argued that cartel-driven “drug enshittification” can only be solved by expanding legal manufacturing competition, whereas another countered that immediate legalization would still cause short-term fatalities and that regulatory change is unlikely.  
- Separately, the channel examined Google’s move to make passkeys (FIDO2/WebAuthn) the default authentication for Google accounts, raising concerns that the scheme effectively mandates carrying a personal surveillance device and cryptographically links all user devices to it.  
- Review of the W3C WebAuthn-1 specification revealed scant public detail on how biometric templates are handled, with Google asserting that “modern devices… cannot package biometric info and send it to the cloud,” yet failing to clarify end-to-end key management or privacy guarantees.